Interleukin Inhibitors Market
Global Interleukin Inhibitors Market Size, Share & Trends Analysis Report by Product Type (IL-1 Inhibitors, IL-5 Inhibitors, IL-6 Inhibitors, IL-17 Inhibitors, and IL-23 Inhibitors), and by Application (Arthritis, Asthma, Eczema, Inflammatory Bowel Disease (IBD), Psoriasis, and Others) Forecast, 2021-2027 Update Available - Forecast 2024-2030
Interleukins are a group of cytokines that were expressed by leucocytes, and they interact between cells of the immune systems. More than 40 cytokines are now designated as interleukins. Cytokines are low molecular weight regulatory proteins or glycoproteins secreted by white blood cells & other cells in the body in response to various stimuli. The global Interleukin Inhibitors market is projected to grow at a modest CAGR of 10.7% during the forecast period (2021-2027). The major aspect that drives the growth of the market includes the various diseases in which interleukins are used for treatment. These are used in the treatment of disorders such as arthritis, asthma, eczema, inflammatory bowel disease (IBD), psoriasis, and others. Hence, the growing prevalence of such disorders is likely to create a wide scope for the growth of the global interleukin inhibitors market over the forecast period.
Further, there has been a paradigm shift in the preferences for the treatment of various disorders, that is, an increased inclination towards the use of targeted therapies for the treatment. Therefore, this is also created significant growth opportunities for the market over the forecast period. Furthermore, the key player's contribution has also supported the market growth. Pipeline products, label extensions of marketed products such as Dupixent for atopic dermatitis, Actemra for juvenile idiopathic arthritis, and many others are also likely to further impact the market growth. In addition, positive results of the ongoing clinical trials indicate the high growth potential of the interleukin inhibitors market over the forecast period.
Segmental Outlook
The global Interleukin Inhibitors market is segmented on the basis of product type and applications. Based on the product type, the market is segmented as IL-1 inhibitors, IL-5 inhibitors, IL-6 inhibitors, IL-17 inhibitors, and IL-23 inhibitors. Based on the applications, the market is segmented as arthritis, asthma, eczema, inflammatory bowel disease (IBD), psoriasis, and others. The segmental growth of the market is accredited to the rising prevalence of various diseases across the globe. For instance, according to the World Psoriasis Day consortium, globally 125 million people, that is, more than 3% of the total population suffer from psoriasis. According to the National Psoriasis Foundation, more than 8 million Americans suffer from psoriasis. Hence, the rising disease burden and demand for proper medicines are some of the factors supporting the segmental growth of the market.
Global Interleukin Inhibitors Market, by Applications 2020 (%)
Regional Outlook
The global Interleukin inhibitors market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. The North American region is projected to hold a significant market share. The US and Canada are the major economies primarily contributing to the growth of the Interleukin Inhibitors market in the region. The regional growth of the market is accredited to the presence of key players such as Eli Lilly and Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck KgaA, AstraZeneca Plc, and Sun Pharmaceutical Industries Ltd. among many others. These players are continuously engaged in R&D activities for the development of novel products.
Besides, proactive government initiatives and an increase in healthcare expenditure in the region are also some of the major drivers for the market growth in the region over the forecast period. Further, the Asia-Pacific region is also likely to substantially register in the growth of the market over the forecast period owing to the various government initiatives concerning the health of the people in the region. For instance, Healthy China 2020 was launched by the Chinese government concerning the health of the people in the country. Hence, this is likely to contribute to the growth of the market over the forecast period.
Global Interleukin Inhibitors Market, by Region 2020 (%)
Market Players Outlook
The prominent players functioning in the global Interleukin Inhibitors market include Eli Lilly and Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck KgaA, AstraZeneca Plc, and Sun Pharmaceutical Industries Ltd. among many others. These key manufacturers are adopting various strategies such as new product launches and approvals, mergers and acquisitions, partnerships and collaborations, and many others in order to thrive in a competitive environment. For instance, in 2019, AbbVie, Inc. introduced Skyrizi (risankizumab-rzaa) to treat plaque psoriasis. Whereas, in 2018, Sun Pharmaceutical introduced Ilumya (tildrakizumab-asmn) for the treatment of plaque psoriasis (moderate-to-severe).
The Report Covers
- Market value data analysis of 2020 and forecast to 2027.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global Interleukin Inhibitors market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Competitive Dashboard
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Eli Lilly and Co.
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. F. Hoffmann-La Roche Ltd.
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. GlaxoSmithKline Plc
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. Johnson and Johnson Services Inc.
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. Novartis AG
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Interleukin Inhibitors Market by Product Type
5.1.1. IL-1 Inhibitors
5.1.2. IL-5 Inhibitors
5.1.3. IL-6 Inhibitors
5.1.4. IL-17 Inhibitors
5.1.5. IL-23 Inhibitors
5.2. Global Interleukin Inhibitors Market by Application
5.2.1. Arthritis
5.2.2. Asthma
5.2.3. Eczema
5.2.4. Inflammatory Bowel Disease (IBD)
5.2.5. Psoriasis
5.2.6. Others (Transplant Rejection)
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. ASEAN
6.3.5. South Korea
6.3.6. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. AbbVie, Inc.
7.2. AstraZeneca Plc
7.3. Bausch Health Co. Inc.
7.4. Bristol–Myers Squibb Co.
7.5. Regeneron Pharmaceuticals, Inc.
7.6. Sanofi SA
7.7. Sun Pharmaceutical Industries Ltd.
7.8. Teva Pharmaceuticals Industries, Ltd
1. GLOBAL INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2020-2027 ($ MILLION)
2. GLOBAL IL-1 INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
3. GLOBAL IL-5 INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
4. GLOBAL IL-6 INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
5. GLOBAL IL-17 INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
6. GLOBAL IL-23 INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
7. GLOBAL INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
8. GLOBAL INTERLEUKIN INHIBITORS FOR ARTHRITIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
9. GLOBAL INTERLEUKIN INHIBITORS FOR ASTHMA MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
10. GLOBAL INTERLEUKIN INHIBITORS FOR ECZEMA MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
11. GLOBAL INTERLEUKIN INHIBITORS FOR INFLAMMATORY BOWEL DISEASE (IBD) MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
12. GLOBAL INTERLEUKIN INHIBITORS FOR PSORIASIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
13. GLOBAL INTERLEUKIN INHIBITORS FOR OTHER APPLICATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
14. GLOBAL INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
15. NORTH AMERICAN INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
16. NORTH AMERICAN INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2020-2027 ($ MILLION)
17. NORTH AMERICAN INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
18. EUROPEAN INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
19. EUROPEAN INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2020-2027 ($ MILLION)
20. EUROPEAN INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
21. ASIA-PACIFIC INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
22. ASIA-PACIFIC INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2020-2027 ($ MILLION)
23. ASIA-PACIFIC INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
24. REST OF THE WORLD INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2020-2027 ($ MILLION)
25. REST OF THE WORLD INTERLEUKIN INHIBITORS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2020-2027 ($ MILLION)
1. GLOBAL INTERLEUKIN INHIBITORS MARKET SHARE BY PRODUCT TYPE, 2020 VS 2027 (%)
2. GLOBAL INTERLEUKIN INHIBITORS MARKET SHARE BY APPLICATION, 2020 VS 2027 (%)
3. GLOBAL INTERLEUKIN INHIBITORS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
4. US INTERLEUKIN INHIBITORS MARKET SIZE, 2020-2027 ($ MILLION)
5. CANADA INTERLEUKIN INHIBITORS MARKET SIZE, 2020-2027 ($ MILLION)
6. UK INTERLEUKIN INHIBITORS MARKET SIZE, 2020-2027 ($ MILLION)
7. FRANCE INTERLEUKIN INHIBITORS MARKET SIZE, 2020-2027 ($ MILLION)
8. GERMANY INTERLEUKIN INHIBITORS MARKET SIZE, 2020-2027 ($ MILLION)
9. ITALY INTERLEUKIN INHIBITORS MARKET SIZE, 2020-2027 ($ MILLION)
10. SPAIN INTERLEUKIN INHIBITORS MARKET SIZE, 2020-2027 ($ MILLION)
11. ROE INTERLEUKIN INHIBITORS MARKET SIZE, 2020-2027 ($ MILLION)
12. INDIA INTERLEUKIN INHIBITORS MARKET SIZE, 2020-2027 ($ MILLION)
13. CHINA INTERLEUKIN INHIBITORS MARKET SIZE, 2020-2027 ($ MILLION)
14. JAPAN INTERLEUKIN INHIBITORS MARKET SIZE, 2020-2027 ($ MILLION)
15. ASEAN INTERLEUKIN INHIBITORS MARKET SIZE, 2020-2027 ($ MILLION)
16. SOUTH KOREA INTERLEUKIN INHIBITORS MARKET SIZE, 2020-2027 ($ MILLION)
17. REST OF ASIA-PACIFIC INTERLEUKIN INHIBITORS MARKET SIZE, 2020-2027 ($ MILLION)
18. REST OF THE WORLD INTERLEUKIN INHIBITORS MARKET SIZE, 2020-2027 ($ MILLION)
